Journal
LUPUS
Volume 10, Issue 11, Pages 779-783Publisher
ARNOLD, HODDER HEADLINE PLC
DOI: 10.1177/096120330101001104
Keywords
systemic lupus erythematosus; lupus; SLE; indole-3-carbinol; metabolic effects
Categories
Funding
- NCRR NIH HHS [M01 RR00533] Funding Source: Medline
- NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000533] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Estrogen metabolism in women with SLE is weighted towards 16 alpha -hydroxyestrone, an estrogenic compound that might fuel disease activity. Indole-3-carbinol (I3C) is a nutritional compound that can shift estrogen metabolism towards less estrogenic metabolites. However, the effects of I3C in women with SLE have not been studied. Open-label 1-week metabolic study of 375mg/day I3C was carried out in women with SLE, followed by a 3-month observational period for disease activity. The primary outcome measure was the change in ratio of urinary 2:16 alpha hydroxyestrone levels. Secondary measures included the SLE Disease Activity Index. Seventeen clinically premenopausal women fulfilling ACR criteria for probable/definite SLE (mean age 37.9y, range 20-49y, mean disease duration 4.3y, range 0.5-15) completed the 1-week metabolic study; 12 took I3C for 3 months. The mean 2:16 alpha hydroxyestrone ratio increased by 1.84 to 3.15 (P=0.0001). Mean SLEDAI scores were 10.0 (baseline); 6.25 (3 months); and 8.8 (3 months after withdrawal; P=NS). Women with SLE can manifest a metabolic response to 13C and might benefit from its antiestrogenic effects. We did not observe any striking effects on SLE disease activity during the 3-month observational period.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available